Skip to content
10-K

Annual Report

Ventyx Biosciences, Inc.

0000950170-25-029245

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 24, 2025 71.13M sh
Shares Diluted FY 2024 · Dec 31, 2024 68.48M sh
Shares Diluted FY 2024 · Dec 31, 2023 58.54M sh
Capex FY 2024 · Dec 31, 2024 $241K
Capex FY 2024 · Dec 31, 2023 $514K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$130.87M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$166.52M
Cash And Equivalents FY 2024 · Dec 31, 2024 $27.26M
Cash And Equivalents FY 2024 · Dec 31, 2023 $51.58M
Stockholders Equity FY 2024 · Dec 31, 2024 $254.05M
Stockholders Equity FY 2024 · Dec 31, 2023 $243.92M
Stockholders Equity FY 2024 · Dec 31, 2022 $353.9M
Current Liabilities FY 2024 · Dec 31, 2024 $12.78M
Current Liabilities FY 2024 · Dec 31, 2023 $22.27M
Total Liabilities FY 2024 · Dec 31, 2024 $22.52M
Total Liabilities FY 2024 · Dec 31, 2023 $33.77M
Current Assets FY 2024 · Dec 31, 2024 $229.63M
Current Assets FY 2024 · Dec 31, 2023 $264.35M
Total Assets FY 2024 · Dec 31, 2024 $276.56M
Total Assets FY 2024 · Dec 31, 2023 $277.69M
Eps Diluted FY 2024 · Dec 31, 2024 −$1.97
Eps Diluted FY 2024 · Dec 31, 2023 −$3.30
Eps Basic FY 2024 · Dec 31, 2024 −$1.97
Eps Basic FY 2024 · Dec 31, 2023 −$3.30
Sga Expense FY 2024 · Dec 31, 2024 $31.45M
Sga Expense FY 2024 · Dec 31, 2023 $32.23M
Rd Expense FY 2024 · Dec 31, 2024 $117M
Rd Expense FY 2024 · Dec 31, 2023 $175.77M
Net Income FY 2024 · Dec 31, 2024 −$135.12M
Net Income FY 2024 · Dec 31, 2023 −$192.96M
Operating Income FY 2024 · Dec 31, 2024 −$148.45M
Operating Income FY 2024 · Dec 31, 2023 −$207.99M